fbpx
 List – 51 Drug Patents that are Expired in 2023

List – 51 Drug Patents that are Expired in 2023

0

Entresto
Sacubitril; Valsartan

Sales:
$1.7 Billion (2018)

PatentsExpiration Date
US8404744July 14, 2023
US8796331July 14, 2023
US7468390November 27, 2023
US8101659January 15, 2025

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corporation
Ingredients: Sacubitril; Valsartan
Treatment: Chronic Heart Failure

Spinraza
Nusinersen Sodiumz

Sales:
$1.724 Billion (2018)

PatentsExpiration Date
US7101993September 05, 2023
US8110560December 05, 2025
US7838657July 11, 2027
US8361977May 27, 2030

Dosage: Solution; Intrathecal
Company: Biogen Idec Inc
Ingredients: Nusinersen Sodium
Treatment: Spinal Muscular Atrophy

Tegsedi
Inotersen Sodium

Sales:
$2.2 Million (Q4, 2018)

PatentsExpiration Date
US7015315March 21, 2023
US7101993September 05, 2023

Dosage: Solution; Subcutaneous
Company: Akcea Therapeutics Inc
Ingredients: Inotersen Sodium
Treatment: Polyneuropathy

Dalvance
Dalbavancin Hydrochloride

Sales:
$81.9 Million (2019)

PatentsExpiration Date
US6900175December 25, 2023
US7115564November 14, 2023
US7119061November 14, 2023
US8143212November 14, 2023

Dosage: Powder; Intravenous
Company: Allergan Sales LLC
Ingredients: Dalbavancin Hydrochloride
Treatment: To Treat Severe Skin Infections

Zykadia
Ceritinib

Sales:
$91 Million (2016)

PatentsExpiration Date
US9416112January 31, 2023
US8188276January 31, 2023
US9018204January 31, 2023
US8835430January 31, 2023
US7893074April 25, 2026
US9018204November 20, 2027
US7964592April 29, 2028
US8039479June 29, 2030
US9309229January 18, 2032

Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Ceritinib
Treatment: Lung Cancer

Promacta
Eltrombopag Olamine

Sales:
$330 Million (Q4, 2018)

PatentsExpiration Date
US7160870May 20, 2023
US7547719January 13, 2026

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Eltrombopag Olamine
Treatment: Thrombocytopenia

Rubraca
Rucaparib Camsylate

Sales:
$142 – $143 Million (2019)

PatentsExpiration Date
US6495541November 22, 2023
US9045487February 10, 2031
US8754072February 10, 2031

Dosage: Tablet; Oral
Company: Clovis Oncology Inc
Ingredients: Rucaparib Camsylate
Treatment: BRCA-Mutated Ovarian Cancer

Mektovi
Binimetinib

Sales:
$35.1 Million (Q3, 2019)

PatentsExpiration Date
US7777050March 13, 2023
US8178693March 13, 2023
US8193229March 13, 2023
US8513293March 13, 2023
US9562016October 18, 2033

Dosage: Tablet; Oral
Company: Array Biopharma Inc
Ingredients: Binimetinib
Treatment: Unresectable or Metastatic Melanoma with a BRAF V600 Mutation

Zosyn
Piperacillin Sodium, Tazobactam Sodium

Sales:
$51 Million (2019)

PatentsExpiration Date
US6900184April 14, 2023
US7915229April 14, 2023
US8133883April 14, 2023

Dosage: Injectable; Injection
Company: Wyeth Pharmaceuticals LLC
Ingredients: Piperacillin Sodium; Tazobactum Sodium
Treatment: Bacterial Infections

Boniva
Ibandronate Sodium

Sales:
$517 Million (2011)

PatentsExpiration Date
US7192938May 06, 2023
US7410957May 06, 2023
US7718634May 06, 2023

Dosage: Injectable; Injection
Company: Hoffmann La Roche Inc
Ingredients: Ibandronate Sodium
Treatment: Osteoporosis

Votrient
Pazopanib Hydrochloride

Sales:
$828 Million (2018)

PatentsExpiration Date
US7105530October 19, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Pazopanib Hydrochloride
Treatment: Soft Tissue Sarcomas and Advanced Renal Cell Carcinoma

Tyzeka
Telbivudine

Sales:
–

PatentsExpiration Date
US7858594September 11, 2023
US7589079September 11, 2023

Dosage: Solution; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Telbivudine
Treatment: Chronic Hepatitis B

Exforge
Amlodipine Besylate; Hydrochlorothiazide; Valsartan

Sales:
$1.025 Billion (2019)

PatentsExpiration Date
US8101599May 16, 2023
US8475839May 16, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Treatment: High Blood Pressure (Hypertension)

Ozurdex
Dexamethasone

Sales:
$33.7 Million (Q3, 2019)

PatentsExpiration Date
US8034366January 09, 2023
US8034370January 09, 2023
US9192511January 09, 2023
US10076526January 09, 2023
US6899717November 01, 2023
US8506987January 09, 2023
US10702539January 09, 2023

Dosage: Implant; Intravitreal
Company: Allergan Inc
Ingredients: Dexamethasone
Treatment: Macular Edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)

Feraheme
Ferumoxytol

Sales:
$41.7 Million (Q4, 2019)

PatentsExpiration Date
US6599498June 30, 2023

Dosage: Solution; Intravenous
Company: Amag Pharmaceuticals Inc
Ingredients: Ferumoxytol
Treatment: Iron Deficiency Anemia

Patanase
Olopatadine Hydrochloride

Sales:
–

PatentsExpiration Date
US7977376February 02, 2023
US8399508September 17, 2022

Dosage: Spray, Metered; Nasal
Company: Novartis Pharmaceuticals Corp
Ingredients: Olopatadine Hydrochloride
Treatment: Congestion, Sneezing, and Runny Nose caused by Seasonal Allergies

Mozobil
Plerixafor

Sales:
$108.3 Million (2018)

PatentsExpiration Date
US6987102July 22, 2023
US7897590July 22, 2023

Dosage: Solution; Subcutaneous
Company: Genzyme Corp
Ingredients: Plerixafor
Treatment: Non-Hodgkin’s Lymphoma or Multiple Myeloma

Oraverse
Phentolamine Mesylate

Sales:
–

Patents Expiration Date
US7229630 June 20, 2023
US7569230 October 17, 2023
Dosage: Injectable; Injection Company: Septodont Holding SAS Ingredients: Phentolamine Mesylate Treatment: Used for Reversal of the Soft-Tissue Anesthesia

Ryzolt
Tramadol Hydrochloride

Sales:
–

PatentsExpiration Date
US7988998October 27, 2023

Dosage: Tablet, Extended Release; Oral
Company: Purdue Pharma Products LP
Ingredients: Tramadol Hydrochloride
Treatment: Severe Pain

Toviaz
Fesoterodine

Sales:
$69 Million (2020)

PatentsExpiration Date
US6858650January 3, 2023

Dosage: Oral
Company: Pfizer
Ingredients: FESOTERODINE FUMARATE
Treatment: Overactive Bladder Syndrome (OAB)

Ibrance
Palbociclib

Sales:
$1.43 Billion (2020)

PatentsExpiration Date
US6936612January 16, 2023
US7208489January 16, 2023
USRE47739March 5, 2027
US10723730February 8, 2034

Dosage: Oral
Company: Pfizer
Ingredients: PALBOCICLIB
Treatment: HR-positive and HER2-negative breast cancer

Vizamyl
Flutemetamol

Sales:
–

PatentsExpiration Date
US7351401January 24, 2023
US8236282May 21, 2024
US7270800September 3, 2025

Dosage: Intravenous
Company: GE Healthcare
Ingredients: FLUTEMETAMOL F-18
Treatment: Used as a Diagnostic Tool for Alzheimer’s disease

Janumet
Sitagliptin/Metformin

Sales:
$5.2 Billion (2020)

PatentsExpiration Date
US6699871January 26, 2023
US7326708May 24, 2027

Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Treatment: Type 2 Diabetes

Lexapro
Escitalopram

Sales:
DKK 1.83 Billion (2021)

PatentsExpiration Date
US6916941February 12, 2023

Dosage: Oral
Company: Lundbeck
Ingredients: ESCITALOPRAM OXALATE
Treatment: Major Depressive Disorder or Generalized Anxiety Disorder

Victoza
Liraglutide

Sales:
DKK 15.05 Billion (2021)

PatentsExpiration Date
US6268343February 22, 2023
US8114833February 13, 2026

Dosage: Subcutaneous
Company: Novo Nordisk
Ingredients: LIRAGLUTIDE RECOMBINANT
Treatment: Type 2 Diabetes, Obesity, and Chronic Weight Management

Fosamax
Alendronic Acid

Sales:
–

PatentsExpiration Date
US7964212March 6, 2023
US7488496August 11, 2023

Dosage: Oral
Company: Merck & Co Inc
Ingredients: ALENDRONATE SODIUM
Treatment: Osteoporosis and Paget’s Disease of Bone

Koselugo
Selumetinib

Sales:
$108 Million (2021)

PatentsExpiration Date
US8178693March 13, 2023
US7425637April 11, 2024
US9562017December 12, 2026
US9156795December 12, 2026

Dosage: Oral
Company: AstraZeneca
Ingredients: SELUMETINIB SULFATE
Treatment: Neurofibromatosis type I (NF-1)

Akynzeo
Netupitant / Palonosetron

Sales:
–

PatentsExpiration Date
US6297375March 17, 2023
US10233154September 25, 2035
US9951016September 25, 2035
US10961195September 25, 2035
US10676440September 25, 2035

Dosage: Oral, Intravenous
Company: Helsinn Therapeutics
Ingredients: NETUPITANT; PALONOSETRON HYDROCHLORIDE
Treatment: Acute and Delayed Chemotherapy-induced Nausea and Vomiting

Kynamro
Mipomersen

Sales:
–

PatentsExpiration Date
US7015315March 21, 2023
US7511131January 29, 2027

Dosage: Subcutaneous Injection
Company: Genzyme Corporation
Ingredients: MIPOMERSEN SODIUM
Treatment: Homozygous Familial Hypercholesterolemia

Incruse Ellipta
Umeclidinium bromide

Sales:
–

PatentsExpiration Date
USRE44874March 23, 2023
US7498440April 27, 2025
US7439393May 21, 2025
US7488827December 18, 2027

Dosage: Inhalation
Company: GlaxoSmithKline
Ingredients: UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)

Xeljanz
Tofacitinib

Sales:
$696 Milllion (2020)

PatentsExpiration Date
US6965027March 25, 2023
USRE41783December 8, 2025

Dosage: Oral
Company: Pfizer
Ingredients: TOFACITINIB CITRATE
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis

Vocabria
Cabotegravir

Sales:
–

PatentsExpiration Date
US8080551April 11, 2023
US7125879April 21, 2025

Dosage: Oral, Intramuscular
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR; RILPIVIRINE
Treatment: HIV/AIDS

Dexilant
Dexlansoprazole

Sales:
–

PatentsExpiration Date
US6664276July 30, 2023

Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease

Dutrebis
Lamivudine/raltegravir

Sales:
–

PatentsExpiration Date
US7820660April 25, 2023

Dosage: Oral
Company: Merck Sharp & Dohme Corp.
Ingredients: LAMIVUDINE; RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS

Fotivda
Tivozanib

Sales:
$38.9 Million (2021)

PatentsExpiration Date
US6821987April 26, 2023
US7166722November 16, 2023

Dosage: Oral
Company: AVEO Pharmaceuticals
Ingredients: TIVOZANIB HYDROCHLORIDE
Treatment: Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC)

Banzel
Rufinamide

Sales:
–

PatentsExpiration Date
US6740669May 14, 2023

Dosage: Oral
Company: Eisai Inc.
Ingredients: RUFINAMIDE
Treatment: Seizures Associated with Lennox-Gastaut syndrome

Nuzyra
Omadacycline

Sales:
–

PatentsExpiration Date
US7553828June 2, 2023
US7326696September 24, 2023
US8383610September 23, 2030

Dosage: Oral, Intravenous
Company: Paratek Pharmaceuticals
Ingredients: OMADACYCLINE TOSYLATE
Treatment: Community-acquired Bacterial Pneumonia and Acute Skin and skin structure infections

Halaven
Eribulin

Sales:
–

PatentsExpiration Date
US6214865July 20, 2023

Dosage: Intravenous
Company: Eisai Inc.
Ingredients: ERIBULIN MESYLATE
Treatment: Breast Cancer and Liposarcoma

Dexilant
Dexlansoprazole

Sales:
–

PatentsExpiration Date
US6664276July 30, 2023

Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease

Onglyza
Saxagliptin

Sales:
$360 Million (2021)

PatentsExpiration Date
USRE44186July 31, 2023

Dosage: Oral
Company: AstraZeneca
Ingredients: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Vyvanse
Lisdexamfetamine

Sales:
271.5 Billion JPY

PatentsExpiration Date
US7659253August 24, 2023
US7655630August 24, 2023
US7662787August 24, 2023

Dosage: Oral
Company: Shire (Takeda)
Ingredients: LISDEXAMFETAMINE DIMESYLATE
Treatment: Attention Deficit Hyperactivity Disorder (ADHD)

Lumigan
Bimatoprost

Sales:
$149 Million (2021)

PatentsExpiration Date
US8038988August 25, 2023
US7851504June 13, 2027
US8629185July 15, 2031

Dosage: Eye Drops
Company: Allergan
Ingredients: BIMATOPROST
Treatment: High Pressure Inside the eye including Glaucoma

Vibativ
Telavancin

Sales:
$11.7 million (2021)

PatentsExpiration Date
US6635618September 11, 2023
US7531623January 1, 2027

Dosage: Intravenous
Company: Theravance Biopharma
Ingredients: TELAVANCIN HYDROCHLORIDE
Treatment: MRSA or other Gram-positive infections

Lupron
Leuprorelin

Sales:
$783 Million (2021)

PatentsExpiration Date
US8470359October 15, 2023

Dosage: Subcutaneous, Intramuscular
Company: AbbVie Inc
Ingredients: LEUPROLIDE ACETATE
Treatment: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids

Feraheme
Ferric Carboxymaltose

Sales:
$167.9 million (2020)

PatentsExpiration Date
US11123321October 20, 2023
US9376505October 20, 2023
US7612109February 5, 2024

Dosage: Intravenous
Company: AMAG Pharmaceuticals
Ingredients: FERRIC CARBOXYMALTOSE
Treatment: Iron-deficiency Anemia

Ozanex
Ozenoxacin

Sales:
–

PatentsExpiration Date
US6335447November 9, 2023

Dosage: Topical
Company: Cipher Pharmaceuticals
Ingredients: OZENOXACIN
Treatment: Impetigo

Stiolto® Respimat
Tiotropium/olodaterol

Sales:
–

PatentsExpiration Date
US7491719November 10, 2023
US7056916December 7, 2023
US7220742May 12, 2025
US7727984January 19, 2027

Dosage: Inhalation
Company: Boehringer Ingelheim Pharmaceuticals
Ingredients: OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
Treatment: Asthma

Otezla
Apremilast

Sales:
$2.2 billion (2020)

PatentsExpiration Date
US7893101December 9, 2023
US7427638February 16, 2028

Dosage: Oral
Company: Amgen Inc
Ingredients: APREMILAST
Treatment: Psoriasis and Psoriatic Arthritis

Rapivab
Peramivir

Sales:
$13.9 million (2020)

PatentsExpiration Date
US6562861December 16, 2023

Dosage: Intravenous
Company: BioCryst Pharmaceuticals
Ingredients: PERAMIVIR
Treatment: Influenza

VYNDAQEL
Tafamidis/Meglumine

Sales:
$429 Million (2020)

PatentsExpiration Date
US8168663December 19, 2023
US7214695April 27, 2024
US9770441August 31, 2035

Dosage: Oral
Company: Pfizer
Ingredients: TAFAMIDIS MEGLUMINE
Treatment: Transthyretin Amyloidosis

Coreg
Carvedilol

Sales:
–

PatentsExpiration Date
US7268156December 27, 2023

Dosage: Oral
Company: GlaxoSmithKline
Ingredients: CARVEDILOL PHOSPHATE
Treatment: High Blood Pressure, Congestive Heart Failure (CHF), and Left Ventricular Dysfunction

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.